Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 October 2026
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 November 2026
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinomaStatus:In development | In consultationProgramme:HealthTech guidanceConsultation end date: 6 July 2026Expected publication date: TBC